Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Effect of hydroxychloroquine in hospitalized patients with Covid-19
Avtorji:ID Horby, Peter (Avtor)
ID Kačar, Mark (Z enoto povezano ime)
ID Mafham, Marion (Avtor)
ID Landray, Martin J. (Avtor)
ID Kačar, Mark (Sodelavec pri raziskavi)
Datoteke:URL URL - Priloga, za dostop obiščite https://www.nejm.org/doi/10.1056/NEJMoa2022926?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#article_supplementary_material
 
URL URL - Izvorni URL, za dostop obiščite https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022926?articleTools=true
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials. Methods: In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality. Results: The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine. Conclusions: Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).
Ključne besede:Covid-19 -- drug therapy, hydroxychloroquine, chloroquine
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:ZDA
Založnik: Massachusetts Medical Society
Leto izida:2020
Št. strani:str. 2030-2040
Številčenje:Vol. 383, iss. 21
PID:20.500.12556/DiRROS-15124 Novo okno
UDK:616.9
ISSN pri članku:1533-4406
DOI:10.1056/NEJMoa2022926 Novo okno
COBISS.SI-ID:109475843 Novo okno
Avtorske pravice:Copyright © 2020, Massachusetts Medical Society
Opomba:Nasl. z nasl. zaslona; Član raziskovalne skupine iz Slovenije: Mark Kačar; Opis vira z dne 27. 5. 2022;
Datum objave v DiRROS:30.05.2022
Število ogledov:1037
Število prenosov:589
Metapodatki:XML DC-XML DC-RDF
:
HORBY, Peter, MAFHAM, Marion in LANDRAY, Martin J., 2020, Effect of hydroxychloroquine in hospitalized patients with Covid-19. The New England journal of medicine [na spletu]. 2020. Vol. 383, no. 21, p. 2030–2040. [Dostopano 12 april 2025]. DOI 10.1056/NEJMoa2022926. Pridobljeno s: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022926?articleTools=true
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:The New England journal of medicine
Skrajšan naslov:New Engl. j. med.
Založnik:Massachusetts Medical Society, NEJM Group
ISSN:1533-4406
COBISS.SI-ID:520038169 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:19.11.2020

Sekundarni jezik

Jezik:Ni določen
Ključne besede:covid-19 -- terapija z zdravili, hidroksiklorokin, klorokin


Nazaj